The University of Michigan Scleroderma Program was organized in 2004 in the Division of Rheumatology, Department of Internal Medicine at the University of Michigan Medical School.
Scleroderma is an inherently complex disease which is best addressed by a multidisciplinary team approach to treatment and research. The University of Michigan Medical School is one of the leading research institutions in the world. Its clinical and scientific assets are extensive, cutting edge and uniquely suited to the needs of the scleroderma community.
The goals of the Scleroderma Program are to develop effective therapies for scleroderma and its complications and to research the causes and mechanisms of disease. It is only through enhanced understanding of disease process that a cure will be possible.
Based in the Division of Rheumatology, faculty from many disciplines, including Pulmonary Medicine, the Pulmonary Hypertension Program of the Division of Cardiology, Pediatric Rheumatology, the Department of Dermatology, the Division of Hand Surgery, the Department of Occupational Therapy; and the University of Michigan Cancer Center, currently participate in Program activities.
The Scleroderma Program provides clinical care, primarily on a consultative basis to patients from Michigan and the Midwest, but also serves as an international referral ce
performance of complex trials designed to improve the quality of life and extend survival. Crucial to this enterprise is refined investigation of the science of outcome measures, which in turn, leads to more robustly designed clinical trials for the future. An effective and talented team has been assembled and a broad portfolio of research is in progress.
Increasing focus is on initiatives in research into the cause and pathobiology of scleroderma. Basic scientists are active at the University of Michigan in areas of direct relevance to scleroderma including the biology of fibrosis, vascular biology, and basic cellular immunology.
The Scleroderma Program at the University of Michigan is dedicated to advancing research and improving care for patients with scleroderma and related diseases.
to About Us - Top